Overview

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune...

Open

$0.00

Prior close

$219.05

Today's high

$0.00

Today's low

$0.00

52 Week high

$225.80

52 Week low

$135.39

News

GlobeNewsWire • 1 day ago • BIIB

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

GlobeNewsWire • 3 days ago • BIIB

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease

MarketBeat • 4 days ago • BIIB

Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience

Seeking Alpha • 4 days ago • BIIB

Biogen Inc. (BIIB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MarketBeat • 6 days ago • BIIB

Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology